INS and type 1 diabetes mellitus: The majority of people with type 1 diabetes require lifelong insulin replacement therapy and have reduced life expectancy and quality of life; their treatment places a substantial economic burden on health services, with direct UK health costs estimated at £1bn in 2010–2011 [2].